the question is whether the daily adherence burden is worth it
A study published in January found the drugs reduced the risk of 42 diseases, including heart disease, cancer, clotting disorders, Alzheimers, chronic kidney disease, addiction and a range of psychiatric conditions
When combined with a reduced-calorie diet and increased physical activity, clinical trials (primarily the STEP 1 trial in adults without diabetes) have shown that Wegovy can help patients lose an average of 1215% of their body weight over 68 weeks, though individual results vary
Legitimacy is not the same as personalization A program can be fully legitimate and still treat two very different bodies the same way
HR teams and benefits leaders should work closely with trusted advisors to: Analyze current obesity- and diabetes-related claims
View Tirzepatide Rybelsus Oral semaglutide option for eligible patients interested in non-injection GLP-1 discussions